Keywords clot-fibrinolysis waveform analysis - coagulation and fibrinolysis - fibrin - tissue-type
plasminogen activator - fibrinolysis
Introduction
A well-controlled balance between procoagulant, anticoagulant, and fibrinolytic mechanisms
is critical for maintaining normal hemostasis in the circulation. If this well-controlled
balance is lost, it may clinically manifest as hemorrhage or thrombosis. In patients
with severe trauma, hemorrhage is usually associated with hyperfibrinolysis in the
early trauma period, while thrombus formation is associated with the activation of
hypercoagulability in the subacute period.[1 ]
[2 ] Moreover, severe coagulopathy immediately after trauma is a predictor of a poor
prognosis.[3 ]
[4 ]
[5 ] In sepsis, a hypercoagulable state occurs, which is characterized by microvascular
thrombi, fibrin deposition, neutrophil extracellular trap formation, and endothelial
damage.[6 ] Furthermore, subsequent consumptive coagulopathy can lead to uncontrolled bleeding.[7 ] In patients with severe sepsis, repeated screening for disseminated intravascular
coagulation (DIC) has, by itself, been associated with an improved prognosis.[8 ] Similarly, in patients with post-cardiac arrest syndrome, coagulation is persistently
activated in the presence of the underlying disease, resulting in diffuse microthrombus
formation in small blood vessels.[9 ] Coagulopathy has also been associated with a poor prognosis in post-cardiac arrest
patients.[10 ]
[11 ]
[12 ] Thus, the variability in coagulation–fibrinolysis mechanisms is particularly large
in critically ill patients, and its relationship with prognosis has been a focus of
attention. It is important to understand the balance between coagulation and fibrinolysis
for planning an appropriate treatment strategy in the emergency and critical care
fields, as the coagulation and fibrinolysis status can change remarkably in critically
ill patients.
Various assay systems such as activated partial thromboplastin time (APTT), prothrombin
time (PT), thrombin time, thromboelastography, and the thrombin generation test have
been used to evaluate the blood coagulation system. Among them, the APTT-clot waveform
analysis (CWA) has been developed as an automated global coagulation assay that the
light transmittance changes are monitored, and the transmittance and the derivative
curves are described with some parameters in the analyzer.[13 ] Several reports show the usefulness of CWA for DIC diagnosis, bleeding risk prediction,
hemostatic monitoring under anticoagulant therapy, and so on.[13 ]
[14 ]
[15 ]
[16 ] Recently, it was also reported that CWA was one of the parameters for predicting
coronavirus disease 2019 (COVID-19)-associated coagulopathy.[17 ] Furthermore, the improved assay called clot-fibrinolysis waveform analysis (CFWA),
a global functional assay system, has been developed to assess coagulation and fibrinolysis
simultaneously lately and detect the fibrinolysis time[18 ]
[19 ] ([Fig. 1 ]). During routine APTT measurements, a sample is mixed with the APTT reagent, including
an activator and phospholipids, and CaCl2 solution is added to the mixture. Once the coagulation reaction is triggered by the
CaCl2 solution, the transmittance decreases until the clot is formed. The transmittance
change is monitored during the reaction, and the clotting time is measured as the
time taken for the reaction until 50% transmittance reduction is reached ([Fig. 1A ]). For CFWA measurements, a tissue-type plasminogen activator (tPA) is included in
the CaCl2 solution. The APTT reagent and CaCl2 solution are added to the sample and mixed, leading to the coagulation reaction and
transmittance change, followed by clot formation, similarly to APTT measurements.
However, the addition of tPA to the CaCl2 solution triggers the fibrinolysis reaction after clot formation, and the transmittance
increases. During this fibrinolysis reaction, the fibrinolysis time is defined as
the time taken to reach 50% transmittance. This assay is conducted using an automated
coagulation analyzer with regular APTT measurements. The benefit of this assay has
been reported in several articles. Oka et al showed that direct oral anticoagulants
(DOACs) affect both the fibrinolysis and coagulation reactions and suggested that
CFWA could be useful for the assessment of the efficacy of DOACs.[18 ] With regard to bleeding disorders, Nogami et al reported that the fibrinolysis reaction
starts before clot formation in factor VIII-deficient plasma and is suppressed by
tranexamic acid.[19 ] Consequently, CFWA has the potential to evaluate the functional fibrinolysis status
of patients.
Fig. 1 The principle of clot-fibrinolysis waveform analysis and fibrinolysis time. The horizontal
and vertical axes show the time (seconds) and transmittance, respectively. (A ) Activated partial thromboplastin time (APTT) measurement: monitoring of transmittance
starts with the addition of the CaCl2 solution 3 minutes after adding the APTT reagent, and the transmittance decreases
because of clot formation. (B ) Clot-fibrinolysis waveform analysis: monitoring of transmittance is started with
the addition of the CaCl2 solution, including recombinant tissue-type plasminogen activator (r-tPA), 3 minutes
after adding the APTT reagent, similarly to APTT measurements. The monitoring of transmittance
is continued after clot formation. After clot formation, plasmin generated by biogenic
and spiked tPA dissolves the clot, and the transmittance increases over the fibrinolysis
reaction phase. The maximum and minimum values of transmittance are defined as 0 and
100%, respectively, and the fibrinolysis time is defined as the time taken to reach
50% transmittance. (C ) Clot-fibrinolysis waveforms and the parameters in the first derivative data. The
curves of the first derivative in the clot-fibrinolysis waveform are described. The
first peak is observed in the coagulation phase, and the maximum value in the coagulation
phase is defined as min1. The second peak at the negative value in the fibrinolysis
phase is also observed. The absolute value is used as FL-min1. These parameters mean
the velocity of coagulation and fibrinolysis reactions, respectively.
The basic characteristics of CFWA have been investigated during the evaluation of
coagulation factor deficiency or drug-spiked samples.[19 ]
[20 ]
[21 ]
[22 ]
[23 ]
[24 ] Although several fibrinolysis biomarkers, such as D-dimer, plasminogen, and α2 -plasmin inhibitor (α2 -PI), are employed in the clinical setting, few studies have shown the relationship
between the fibrinolysis time detected using CFWA and fibrinolysis markers. Previous
reports, especially in the emergency and critical care settings, are limited and have
only included patients with COVID-19 and sepsis.[25 ]
[26 ] It is important to investigate the characteristics of CFWA by comparing the parameters
with the current markers used in clinical laboratories and to understand the patient's
coagulation and fibrinolysis status from the data collected. This study aimed to investigate
the characteristics of CFWA using blood samples collected from critically ill patients
who had disorders of both the coagulation and fibrinolytic systems due to various
underlying severe acute illnesses. This was achieved by comparing the CFWA parameters
with several coagulation and fibrinolysis markers.
Materials and Methods
Plasma Samples
Patients who were transported to a tertiary emergency facility and admitted to the
intensive care unit from September to December 2014 were included. Blood samples were
collected at the time of admission to the hospital and during the hospitalization
without any restriction. Whole blood samples were collected in plastic tubes containing
3.2% sodium citrate in a 9:1 ratio, and platelet-poor plasmas were obtained after
the centrifugation. In total, 298 clinical samples were prepared and stored at −80
°C. As a control group, 50 healthy donor samples from CRYOcheck Normal Donor Set (Precision
BioLogic Inc., Dartmouth, Canada) were used to establish the normal reference interval.
All plasma samples were stored at −80 °C and thawed at 37 °C immediately before the
assays.
Written informed consent was obtained from all patients who provided the plasma samples.
The study protocol was approved by our Institutional Review Board (approval number:
019-0354).
CFWA Method
The detailed method of CFWA has been described elsewhere.[19 ] Briefly, alteplase (Kyowa Kirin, Tokyo, Japan), which is recombinant tPA (r-tPA),
was diluted with distilled water and then added to Thrombocheck CaCl2 solution (Sysmex Corporation, Kobe, Japan) to achieve a final concentration of 4.1 μg/mL
in the Thrombocheck CaCl2 solution. The CaCl2 solution with r-tPA was prepared every 2 hours according to the previous study.[16 ] Each plasma sample (50 μL) was mixed with 50 μL of Thrombocheck APTT-SLA (Sysmex
Corporation), including the activator and phospholipids, and incubated for 3 minutes
at 37 °C. Then, the CaCl2 solution with r-tPA was added to the sample, and the transmittance change was monitored
at 660 nm wavelength. All measurements were conducted on an automated coagulation
analyzer CS-5100 (Sysmex Corporation). For determining the fibrinolysis time, the
maximum and minimum values of transmittance were defined as 0 and 100% in the clot-fibrinolysis
waveform, respectively; the time taken to reach 50% of the transmittance at the middle
point between 0 and 100% on the curve was defined as the fibrinolysis time in accordance
with previous studies[6 ]
[7 ] ([Fig. 1 ]). Besides the fibrinolysis time, two kinds of parameters were calculated from the
derivative curve in the transmittance results according to the previous study.[16 ] The first derivative curve of the transmittance data was described, and the absolute
maximum values in the coagulation and fibrinolysis phases were calculated ([Fig. 1C ]). These absolute maximum values, defined as min1 and fibrinolysis min1 (FL-min1),
indicate the maximum velocity in the coagulation and fibrinolysis reactions, respectively.
The ratios of min1/FL-min1 were also calculated to express the balance between coagulation
and fibrinolysis reactions.
Laboratory Measurements
Various examinations were performed on all 298 samples with the following reagents:
Revohem PT (PT), Thrombocheck Fib(L) (fibrinogen, Fbg), Auto LIA FM (fibrin monomer
complex, FMC), Revohem Plasminogen (plasminogen, Plg), Lias Auto D-Dimer Neo (D-dimer),
Lias Auto PIC (plasmin–α2 plasmin inhibitor complex, PIC), and Revohem α2 -antiplasmin α2 -PI), which were all obtained from Sysmex Corporation. The reference values recommended
by the manufacturer were 9.6 to 13.1 seconds for PT, 200 to 400 mg/dL for Fbg, ≤6.1 μg/mL
for FMC, 80 to 130% for Plg, ≤1.0 μg/mL for D-dimer, and ≤0.8 μg/mL for PIC. All measurements
were conducted using the CS-5100 instrument (Sysmex Corporation). As additional testing,
tPA and plasminogen activator inhibitor-1 (PAI-1) were also measured for 237 samples
with enough volume; the remaining 61 samples did not have enough volume for the tests.
Human Tissue-type Plasminogen Activator (tPA) Chromogenic AssaySense Activity Assay
Kit and Human Plasminogen Activator Inhibitor-1 (PAI-1) Chromogenic AssaySense Activity
Assay Kit were purchased from ASSAYPRO (St. Charles, Missouri, United States) and
used. tPA/PAI-1 ratios and their concentrations were also calculated to express the
balance between enhanced and suppressed fibrinolysis status. The descriptions of the
measurement components of the present study are presented in [Table 1 ].
Table 1
Components of coagulation and fibrinolytic system measured in the present study
Components
Description
D-dimer
It is the degradation of stabilized fibrin by plasmin, indicating an enhanced secondary
fibrinolytic reaction
Fibrinogen (Fbg)
It is a precursor to fibrin, which forms fibrin under the action of thrombin
Fibrin monomer complex (FMC)
It is an indicator that trace amounts of thrombin have been produced, an indicator
of hypercoagulability
Plasminogen (Plg)
It is a zymogen of plasmin, which is the major enzyme that degrades fibrin clots
a2 -Plasmin inhibitor (a2-PI)
It is a primary and fast inhibitor of plasmin, which is an important enzyme to degrade
fibrin clots
Plasmin a2-PI complex (PIC)
It is a complex of plasmin and a2-PI. Its elevation indicates production of plasmin
Statistical Analysis
The normal reference interval range of fibrinolysis time was established from the
data of 50 healthy donor samples, and the lower and upper limits of mean ± 2 standard
deviation (SD) were defined as the cut-off values, respectively. The measurement data
of the 298 clinical samples were divided into three groups based on two kinds of cut-off
values: less than the lower limit of the normal reference interval (shortened group),
within the normal reference interval (within group), and higher than the upper limit
of the normal reference interval (prolonged group). In the shortened group, the clot
was dissolved earlier than the normal range from coagulation activation. In contrast,
the clot dissolved later than the normal range from coagulation activation in the
prolonged group. The values were compared among these three groups using the Kruskal–Wallis
test and Bonferroni's multiple comparison test, and p <0.05 was used to denote statistical significance.
Results
The normal reference interval of fibrinolysis time calculated using 50 healthy donor
samples was 225.7 to 317.8 seconds. The number of samples in the shortened, within,
and prolonged groups was 61, 102, and 135, respectively. In addition, the mean ± SD
values of fibrinolysis time in the same three groups were 199.1 ± 21.6, 274.0 ± 27.0,
and 434.4 ± 105.4 seconds, respectively. Background data on age, sex, and causative
disease of the patients in each group are presented in [Table 2 ].
Table 2
Baseline characteristics of patients by group
Shortened group
(n = 61)
Within group
(n = 102)
Prolonged group
(n = 135)
Age, y
63 (37–78)
66 (38–76)
67 (48–75)
Gender; male (%)
30 (49.2)
66 (64.7)
114 (84.4)
Causative disease, n (%)
Post-cardiac arrest syndrome
15 (24.6)
38 (37.3)
51 (37.8)
Hemorrhagic shock
11 (18.0)
5 (4.9)
5 (3.7)
Trauma
13 (21.3)
31 (30.4)
21 (15.6)
Poisoning
10 (16.4)
4 (3.9)
7 (5.2)
Sepsis/septic shock
3 (4.9)
15 (14.7)
21 (15.6)
Aortic diseases
3 (4.9)
1 (1.0)
2 (1.5)
Cardiogenic shock
4 (6.6)
4 (3.9)
7 (5.2)
Others
2 (3.3)
4 (3.9)
21 (15.6)
Note: Data presented as median (25th–75th percentile), percentage, or numbers.
Comparisons of the coagulation and fibrinolysis markers among the three groups are
shown in [Fig. 2 ]. For the coagulation reaction markers, the Fbg level increased in the order of shortened,
within, and prolonged groups, and the increase was statistically significant among
all three group pairs. The opposite tendency was observed for the FMC; the values
significantly decreased as the CFWA was prolonged in all pair comparisons among the
three groups. Among the fibrinolysis markers, the level of α2 -PI, a serine protease inhibitor of plasmin, also significantly increased as the CFWA
was prolonged when comparing the shortened and within groups and shortened and prolonged
groups. Furthermore, the level of Plg, the precursor of plasmin with the ability to
dissolve Fbg, exhibited a similar tendency to that of α2 -PI; the changes were statistically significant among all three pair comparisons.
PIC, which usually increases during the fibrinolysis reaction after plasmin is inhibited
by the α2 -PI, showed a statistically higher value in the prolonged group than in the within
group, and no other significant differences were detected among other group pairs.
Additionally, no statistically significant differences were observed in D-dimer measurements
among all three group pairs. As for the coagulation screening test, no significant
difference was noted in PT, indicating that the coagulation backgrounds were similar
among the three groups. The values of APTT were also similar among the three groups,
indicating that the prolongation of fibrinolysis time was derived from only fibrinolysis
time prolongation and not from the clotting time.
Fig. 2 Distribution of coagulation and fibrinolysis parameters among the three groups classified
according to the fibrinolysis time in clot-fibrinolysis waveform analysis. Samples
were divided into three groups based on the reference interval (RI) established as
mean ± 2 SD of the fibrinolysis time in the healthy plasma samples as follows: less
than the lower limit of RI (shortened group), within the RI (within group), and higher
than the upper limit of RI (prolonged group). p- Value <0.05 was used to define statistical significance. SD, significant difference.
For the CFWA parameters of min1, FL-min1, and min1/FL-min1, the values were compared
among three groups with the normal reference ranges calculated as the control groups
([Table 3 ]). The median values of min1 and min1/FL-min1 were increased in the order of shortened,
within, and prolonged groups, although the value of FL-min1 in the within group was
equivalent to that of the prolonged group. Moreover, the medians of fibrinolysis time,
min1, and min1/FL-min1 in the within group were close to the normal reference level.
However, the FL-min1 value was higher than the normal reference level, indicating
that the fibrinolysis reaction in the within group differed from that of normal samples.
Overall, statistical differences were observed in all parameters, and it was recognized
that the balance between coagulation and fibrinolysis reactions was different among
the three groups. The fibrinolysis reaction would be enhanced as the fibrinolysis
time is shortened. For tPA and PAI-1, 51, 81, and 105 samples were used for the tests
in the shortened, within, and prolonged groups, respectively ([Fig. 3 ]). Although the significant difference was recognized in only tPA between shortened
and prolonged groups, the median values of tPA/PAI-1 were 2.440, 2.174, and 1.214,
respectively. The values were decreased as the fibrinolysis times were prolonged,
indicating that the shortened and prolonged groups have high and low tPA activity,
respectively.
Fig. 3 Distribution of PAI-1 and tPA among the three groups classified according to the
fibrinolysis time in clot-fibrinolysis waveform analysis. The distributions of PAI-1
and tPA in the shortened (n = 51), within (n = 81), and prolonged (n = 105) groups were described. There was a significant difference in tPA between the
shortened and prolonged groups; there were no significant differences in PAI-1 or
tPA/PAI-1 ratio among the three groups. tPA, tissue plasminogen activator.
Table 3
Comparison of CFWA parameters among shortened, within RI, and prolonged groups with
normal reference ranges
Control
Shorten
(n = 61)
Within
(n = 102)
Prolonged
(n = 135)
p- Value
Fibrinolysis time
274.4 (249.5–283.7)
205.2 (188.0–214.6)
273.9 (252.4–294.1)[a ]
404.4 (362.9–481.8)[a ]
[b ]
<0.001
Min1
4.75 (4.24–5.39)
2.85 (2.31–3.80)
5.68 (4.33–6.86)[a ]
7.30 (5.69–8.47)[a ]
[b ]
<0.001
FL-min1
0.27 (0.26–0.28)
0.28 (0.19–0.34)
0.37 (0.31–0.41)[a ]
0.35 (0.24–0.47)[a ]
<0.001
Min1/FL-min1
17.80 (16.75–18.56)
10.78 (8.34–12.91)
15.49 (13.55–17.57)[a ]
20.16 (16.64–25.51)[b ]
<0.001
Abbreviation: CFWA, clot-fibrinolysis waveform analysis; FL-min1, fibrinolysis min1;
RI, reference interval.
Note: Data presented as median (25th–75th percentile). Control groups are shown as
reference and not statistically compared.
a Statistically significant difference between the shortened group (Bonferroni method).
b Statistically significant difference between the within group (Bonferroni method).
Discussion
In this study, we investigated the relationship of CFWA with the related coagulation
and fibrinolysis parameters in critically ill patients. For comparison, we defined
three groups, shortened, within, and prolonged, according to the fibrinolysis time
determined using CFWA. In the shortened group, we observed an increase in the FMC
level and a decrease in Fbg, Plg, and α2 -PI levels. This indicates the activation of coagulation and fibrinolysis because
FMC is generated from Fbg by thrombin in the coagulation reaction, and the decrease
in Plg and α2 -PI levels indicates their consumption by conversion of Plg to plasmin and inhibition
of plasmin in the fibrinolysis reaction.[27 ]
[28 ]
[29 ] The values of Fbg, α2 -PI, and Plg in the prolonged group were higher than those in the shortened group,
while the value of FMC was lower than that in the shortened group. This suggests that
the coagulation and fibrinolysis status of patients in the prolonged group was the
opposite of that of the patients in the shortened group while also being different
from that of the within group. The mean values of PIC and D-dimer were higher than
the cut-off values in all three groups, indicating the generation of plasmin and fibrin
degradation products in most of the samples due to the fibrinolysis reaction. Although
the fibrinolysis reaction was noted in all three groups, the status was different
among the three groups because the levels of fibrinolysis markers were significantly
different. The fibrinolysis situation with low and high values of Plg and α2 -PI markers indicates the consumption and suppression of these proteins due to several
factors, respectively. Therefore, the shortened and prolonged groups were characterized
by enhanced and suppressed fibrinolysis compared to the within group, respectively.[6 ] Although several methods have been proposed to define the status of enhanced and
suppressed fibrinolysis, specific markers are still required for the classification.[6 ] Alternatively, the groups divided according to the CFWA results showed enhanced
and suppressed fibrinolysis situations in the shortened and prolonged groups, respectively.
In addition, the min1/FL-min1 ratios increased in the order of shortened, within,
and prolonged groups, in which the tendency is consistent with that of fibrinolysis
times. This indicates that the ratios and fibrinolysis times may reflect the fibrinolysis
status. It was confirmed that the ratio parameter calculated from min1 and FL-min1
expressed the balance of comprehensive coagulation and fibrinolytic potential.[25 ] Thus, CFWA has the potential to classify patients according to the fibrinolysis
situation by using only one assay. Recently, Onishi et al suggested that min1 and
FL-min1 parameters were related to the severity in patients with COVID-19, and the
assay could provide information about the hemostatic changes and disease status in
patients with COVID-19.[25 ] Furthermore, it was also reported that CFWA reflected the effects of some drugs
like argatroban, thrombomodulin, and tranexamic acid dose-dependently.[19 ] The drug concentrations and the effects of these drugs in blood might be useful
in some cases, in which CFWA results also have the potential to estimate the drug
effects and contribute to the decision-making in the therapeutic intervention.
Understanding the fibrinolysis situation is important for the diagnosis and treatment
of critically ill patients because strong fibrinolytic activation is observed in various
clinical settings. For example, in patients with trauma and out-of-hospital cardiac
arrest, strong fibrinolytic activation is frequently observed on arrival at the emergency
department.[30 ]
[31 ]
[32 ]
[33 ]
[34 ] The fibrinolytic activation in patients with out-of-hospital cardiac arrest is induced
by the massive release of tPA, with a level up to 250 times that of healthy individuals.[31 ] In patients with severe trauma, marked fibrinolytic activation is observed, but
the total tPA concentration is increased by only approximately 30 times that in healthy
individuals.[33 ] However, in the CFWA protocol used in this study, a large amount of tPA was added
to the sample at the time of measurement, and the final concentration of tPA in the
reaction sample was 1.37 µg/mL. The physiological tPA concentration in vivo is 720
pg/mL[35 ]; thus, the final concentration of tPA in the reaction solution was approximately
1,900 times the physiological concentration. Therefore, the patient-derived tPA amounts
in the CFWA reaction solution were considered negligibly small, and this CFWA measurement
system was considered not to reflect the patient-derived tPA.
One of the important markers of the fibrinolysis reaction is PAI-1, which inhibits
plasminogen activators such as tPA and urokinase-type plasminogen activator. It has
been reported that the PAI-1 concentration increases in critically ill patients, and
it is thought that the elevated PAI-1 inhibits the tPA generated in the patients and
also suppresses the fibrinolysis reaction.[36 ]
[37 ]
[38 ] However, it has also been shown that PAI-1 is not elevated in patients with out-of-hospital
cardiac arrest and trauma in the early phase.[1 ]
[39 ] Inflammation induces the activation of coagulation and increases the levels of several
coagulation markers, including PAI-1 and Fbg.[40 ]
[41 ]
[42 ] In this study, tPA was significantly higher in the shortened group, and both PAI-1
and tPA tended to decrease from shortened to prolonged. The decrease in these levels
may be due to changes in the pathophysiology of the patients. However, to clarify
this, it is necessary to include the causative disease and investigate the pathophysiology
of the patients in the time course as independent variables, which requires a very
large sample size and is a subject for future research.
Limitations
This study had some limitations. First, this study was conducted at a single institution,
and the number of patients may not be sufficiently large. Second, the patient samples
were collected without any restriction during the hospitalization, and the sample
collection timing might affect the results among the three groups. Third, the fibrinolysis
situation in each patient was not defined and classified. Therefore, the evaluation
of the defined samples should be planned in future studies.
Conclusion
In the intensive care setting, CFWA is considered a global fibrinolytic assay that
reflects the Plg and α2 -PI levels in patients. Furthermore, CFWA is not affected by endogenous tPA because
r-tPA is added during the measurement. CFWA can sensitively detect the activation
of the fibrinolytic reaction that is associated with the coagulation reaction, suggesting
that CFWA may be a useful marker for the classification of the fibrinolysis status
of patients.
What is known about this topic?
What does this paper add?
The fibrinolysis time of CFWA reflects plasminogen and α2 -plasmin inhibitor levels.
CFWA is not affected by the endogenous tissue-plasminogen activator.
CFWA has the potential to reflect the fibrinolysis status in one global assay.
